Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors
- 11 November 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 54 (3) , 369-376
Abstract
Purpose: To evaluate the prognostic impact of large cell/anaplastic (LC/A) histology together with molecular and clinical risk factors in childhood medulloblastoma.Methods: Three consecutive prospective medulloblastoma trials were screened for patients with the histological diagnosis of LC/A medulloblastoma. Tumors were considered as LC/A if they displayed areas of severe cytological anaplasia or a significant or predominant large cell component. Histology was centrally confirmed. Genomic DNA amplification of c‐myc and n‐myc, and mRNA expression of c‐myc and trkC were analyzed.Results: Twenty‐eight patients with LC/A medulloblastoma with a median age of 6.1 years (1.4–16.5 years) and a median follow‐up of 4.5 years were identified (5% of all medulloblastoma). Four‐year event‐free (EFS) and overall survival (OS) were 58% and 67%. Young age and metastases (n = 13, 4‐year EFS 31% vs. 82% in 15 children >4 years and without metastases, P = 0.001), large cell histology (n = 9, 4‐year EFS 22% vs. 75%, P = 0.005) and c‐myc amplification (n = 9, 4‐year EFS 22% vs. 89%, P < 0.0001) were negative prognostic factors. C‐myc amplification was highly correlated with young age (P < 0.001), metastases (P = 0.002) and large cell histology (P = 0.007). Outcome of 12 patients with severely anaplastic tumors without these risk factors was not impaired (4‐year EFS 86%).Conclusion: In a subgroup of patients without clinical and molecular risk factors outcome was favorable despite severely anaplastic histology. In contrast, c‐myc amplification and large‐cell histology were associated with an inferior outcome. Intensified treatment strategies should be considered for children with LC/A medulloblastoma and these characteristics. Pediatr Blood Cancer 2010;54:369–376.Keywords
Funding Information
- German Children's Cancer Foundation
- Swiss National Fonds and the Swiss Research Foundation Child and Cancer
- Competence Network Pediatric Oncology
- BONFOR Programme of the Medical Faculty, Rheinische Friedrich-Wilhelms-University, Bonn
This publication has 28 references indexed in Scilit:
- Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91Clinical Cancer Research, 2007
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- c-Myc Overexpression Causes Anaplasia in MedulloblastomaCancer Research, 2006
- A Clinicobiological Model Predicting Survival in MedulloblastomaClinical Cancer Research, 2004
- Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma PatientsClinical Cancer Research, 2004
- Histopathologic grading of medulloblastomasCancer, 2002
- Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic featuresJournal of Neurosurgery, 2001
- C-MYC expression in medulloblastoma and its prognostic valueInternational Journal of Cancer, 2000
- Neurotrophin Receptor TrkC Predicts Good Clinical Outcome in Medulloblastoma and Other Primitive Neuroectodermal Brain TumorsKlinische Padiatrie, 2000
- Large-Cell MedulloblastomasAmerican Journal of Surgical Pathology, 1992